Engineered extracellular vesicles for delivery of siRNA promoting targeted repair of traumatic spinal cord injury

Spinal cord injury (SCI) is a severe disease of the nervous system that causes irreparable damage and loss of function, for which no effective treatments are available to date. Engineered extracellular vesicles (EVs) carrying therapeutic molecules hold promise as an alternative SCI therapy depending on the specific functionalized EVs and the appropriate engineering strategy. In this study, we demonstrated the design of a drug delivery system of peptide CAQK-modified, siRNA-loaded EVs (C-EVs-siRNA) for SCI-targeted therapy. The peptide CAQK was anchored through a chemical modification to the membranes of EVs isolated from induced neural stem cells (iNSCs). CCL2-siRNA was then loaded into the EVs through electroporation. The modified EVs still maintained the basic properties of EVs and showed favorable targeting and therapeutic effects in vitro and in vivo. C-EVs-siRNA specifically delivered siRNA to the SCI region and was taken up by target cells. C-EVs-siRNA used the inherent anti-inflammatory and neuroreparative functions of iNSCs-derived EVs in synergy with the loaded siRNA, thus enhancing the therapeutic effect against SCI. The combination of targeted modified EVs and siRNA effectively regulated the microenvironmental disturbance after SCI, promoted the transformation of microglia/ macrophages from M1 to M2 and limited the negative effects of the inflammatory response and neuronal injury on functional recovery in mice after SCI. Thus, engineered EVs are a potentially feasible and efficacious treat-ment for SCI, and may also be used to develop targeted treatments for other diseases.

Automated summary

In this study, a drug delivery system using engineered extracellular vesicles (EVs) carrying CAQK-modified peptide and loaded siRNA (C-EVs-siRNA) was designed for targeted therapy of spinal cord injury (SCI). The modified EVs effectively delivered siRNA to the SCI region and showed favorable therapeutic effects. The combination of targeted modified EVs and siRNA enhanced the anti-inflammatory and neuroreparative functions of EVs, promoting functional recovery in mice after SCI. This study highlights the potential of engineered EVs as a feasible and efficacious treatment for SCI and possibly other diseases.